The pharmaceutical group has given the two funds applying for the acquisition of its non-prescription medicines subsidiary until Friday evening to review their offers.
Sanofi is requesting new offers for the sale of Doliprane. According to information from BFM Business, the pharmaceutical group wants the PAI and CD&R funds, both candidates for the takeover of Opella, its non-prescription medicines subsidiary, to improve their proposals. It seeks to secure very sensitive social aspects in the current political context.
Sanofi has given the two candidates until Friday evening to submit new offers. The PAI and CD&R funds are invited, of course, to improve the price they proposed, around 15 billion euros.
Sanofi wants to give guarantees to the government
But the owner of Doliprane especially wants them to make strong commitments on social issues in France. Maintaining the two factories and 1,000 jobs over several years as well as supply guarantees, as required by the government.
Why does Sanofi want to sell its Doliprane factories?
Sanofi wants to give assurances to the executive to counter any controversy. But also to prevent it from sending Bbifrance to the capital of its subsidiary to keep an eye on it. The pharmaceutical group also wants to ensure that it will retain veto rights over the strategic decisions of the buyer while it will only retain 49% of the capital of its subsidiary. Sanofi’s choice, between PAI and CD&R, is then expected quickly.
Related News :